Advertisement

Topics

Companies Related to "Therapeutic Induction of Endogenous Antibiotics" [Most Relevant Company Matches] RSS

21:28 EST 14th November 2018 | BioPortfolio

Here are the most relevant search results for "Therapeutic Induction of Endogenous Antibiotics" found in our extensive corporate database of over 50,000 company records.

Showing "Therapeutic Induction Endogenous Antibiotics" Companies 1–25 of 1,900+

Relevant

Complexa, Inc.

Complexa, Inc. is a platform biopharmaceutical company researching and developing endogenous human cell signaling technologies targeting an array of prevalent inflammatory and metabolic diseases. The company’s proprietary technology involves the synthesis and therapeutic applications of endogenous nitro-fatty acids (NFAs) and additional structure/func...


GeNeuro

GeNeuro is a Swiss-based company created by Eclosion in 2006 as a spin-off of bioMérieux and co-funded by Eclosion and the Institut Mérieux. GeNeuro is developing first-in-class therapies against diseases associated with human endogenous retroviruses expression. Its lead product GNbAC1 targets MSRV-ENV protein closely linked to the onset and developm...

Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for


Protez Pharmaceuticals

Protez Pharmaceuticals develops new antibiotics to combat the growing problem of drug resistance, as well as agents that improve the efficacy of current antibiotics.Our focus is difficult-to-treat hospital-based infections. In the United States alone, over eight million people are hospitalized with bacterial infections each year, accounting for greater then 90 million days of therapy. Many of thes...

HANFORD PHARMACEUTICALS

In hospitals across America, physicians manage the risks of infection with a wide range of antibiotics at their disposal.Many of these antimicrobials remain patent-protected and available only from their innovators. But a greater number of still-valuable agents are off-patent or licensed for supply from additional producers.Hanford Pharmaceuticals, founded in 1846 in Upstate New York and still pri...

Caerus Discovery LLC

Caerus Discovery LLC is a privately owned company based on the Prince William Campus of George Mason University in Manassas, VA. Caerus is focused on the discovery of new molecular targets for cancer, autoimmune, inflammatory and infectious diseases. Caerus plans to further develop and optimize novel discovery paradigms employing immune tolerance induction...

Genetic Immunity, LLC

Genetic Immunity is a biopharmaceutical company focused on therapeutic vaccine development and commercialization. The lead product, DermaVir vaccine patch, is under clinical evaluation in Hungary and in the USA for the treatment for HIV/AIDS, where resistance, toxicity, adherence and cost limit the use of drugs. The Company’s vaccine composition mimics the successful induction of antiviral immun...

Ocugen, Inc.

Ocugen is advancing novel biologicals discovered based on endogenous proteins with well understood biology at the molecular, cellular, and whole animal level to treat eye diseases. The therapeutic proteins in the pipeline are derived from cell survival factors such as lens epithelium derived growth factor (LEDGF) and anti-angiogenic proteins such as tumsta...

Helperby Therapeutics Ltd Helperby Therapeutics

Helperby is a biopharmaceutical company dedicated to developing the next generation of lifesaving antibiotics. Helperby’s unique antibiotic technology outsmarts highly resistant bacteria by combining new resistance breakers with old antibiotics to create a whole new generation of therapies. The Company was spun out of St George’s University Hospi...

Translate Bio

Translate Bio is a leading biotechnology company focused on pioneering the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases. The company’s RNA platforms for powering endogenous therapeutic protein production is applicable to a broad range of diseases caused by insufficie...

IntraBiotics Pharmaceuticals Incorporated

The mission of IntraBiotics is to develop and commercialize novel antibacterial and antifungal drugs for the prevention or treatment of serious infectious diseases. IntraBiotics has developed two new antibiotics, Ramoplanin Oral and Protegrin IB-367 Rinse, to the third stage of clinical trials. Ramoplanin Oral and Protegrin IB-367 Rinse are both new types of antibiotics that may address major medi...

Tyme, Inc.

Tyme is a pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications. Tyme is the originator of what it believes to be a novel, proprietary treatment regimen consisting of a rationally-designed combination of therapeutic agents aimed at exploiting the aberrant metabolic charact...

Tyme Technologies, Inc.

Tyme, Inc. is a pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications. Tyme, Inc. is the originator of what it believes to be a novel, proprietary treatment regimen consisting of a rationally-designed combination of therapeutic agents aimed at exploiting the aberrant metab...

Puracyp, Inc.

Puracyp began operations in 1993 focusing on the distribution of monospecific inhibitory antibodies to several human P450 enzymes. Members of the pharmaceutical industry used these antibodies to assess the contribution of a single P450 enzyme to a drug metabolizing reaction. Researchers also used anti-human P450 immunoglobulins in Western blotting experiments to determine expression of individual ...

CytomX Therapeutics

CytomX Therapeutics is an early stage biotechnology company developing Probodies™, or proteolytically-activated antibodies. Probodies combine the well-established power and specificity of monoclonal antibodies with a second level of tissue selectivity, driven by the action of endogenous disease enzymes. Probodies, by their ability to site-direct the activity...

Genervon Biopharmaceuticals, LLC

Genervon has discovered a novel endogenous embryonic stage family of 9 human Master Regulators of the Nervous System. It has obtained 46 Composition of Matter and Use patents.

Oasmia Pharmaceutical AB

Oasmia Pharmaceutical (publ) is a pharmaceutical company based on the latest concepts of bioorganic chemistry. Our business idea is to improve treatment of common and serious diseases with focus on oncology. This is performed by development of the semi-synthetic substances discovered by the company into a new generation of efficient drugs for different therapeutic areas.A main ambition is to devel...

Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals is a clinical stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs for serious infections such as drug resistance and gram-negative infections. The company has developed an emerging pipeline of p...

Probably Relevant

Traversa Therapeutics

Traversa Therapeutics, Inc. (www.traversathera.com) is a San Diego, California-based biopharmaceutical company engaged in the discovery, development and commercialization of RNAi technologies. The company strives to rapidly advance siRNA platform delivery technologies for use in its internal oncology programs and by sanofi-aventis in targeting a wide varie...

CKE Restaurants Holdings, Inc.

Over the past several years, Carl’s Jr. and Hardee’s have established themselves as pioneers of the movement toward offering cleaner, all-natural menu items at fast food restaurants, having become the first major QSR chains to introduce an all-natural, grass-fed beef burger with no added hormones, antibiotics, or steroids at Carl’s Jr. in 20...

Keep Antibiotics Working

Rib-X Pharmaceuticals, Inc

Rib-X Pharmaceuticals,Inc. is a small molecule drug discovery and development company focused on the structure-based design of novel classes of antibiotics. We are building a pipeline of diverse products that are suitable for treatment of a wide range of antibiotic-resistant infections found in either hospital or community settings. The Rib-X competitive advantage is our detailed and proprietary k...

Peptilogics

Peptilogics is an early-stage biotechnology company developing a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Through rational design, this technology dramatically amplifies the antimicrobial activity of naturally-occu...

Alliance for the Prudent Use of Antibiotics (APUA)

Banyu Pharmaceutical Company Limited

Antibiotics


More From BioPortfolio on "Therapeutic Induction of Endogenous Antibiotics"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks